New progress of cabozantinib in the treatment of metastatic renal cell carcinoma / 国际肿瘤学杂志

ABSTRACT

Renal cell carcinoma (RCC),the most common form of kidney cancer,is characteristic by difficult in diagnosis at an early stage,insensitivity to chemoradiotherapy,poor prognosis,etc. . Localized RCC is treated by surgery while advanced RCC is mainly treated by immunotherapy and targeted therapy. With the ongoing in-depth researches on targeted therapy in recent years,plenty of targeted drugs come into the market in succession. Cabozantinib has been approved for the treatment of advanced RCC in the first/ second line setting. It's safety profile and efficiency have been demonstrated in Ⅱ-Ⅲ clinical trials.